Madeglucyl is produced from the seeds of Eugenia jambolana (also known as Syzygium cumini), an edible plant used as a remedy in Madagascar folk medicine, according to the company.
Indena said that the efficacy of Madeglucyl has been made clear during clinical tests carried out in Madagascar, the US and Germany, where the supplement apparently demonstrated "a good tolerability and a significant effect 15 days after starting the treatment".
Meanwhile, toxicological and pharmacological data appeared to confirm that Madeglucyl is devoid of any side effects and can provide a support in maintaining normal sugar levels in several experimental conditions.
Paolo Morazzoni, Indena's scientific director, said that Madeglucyl "can provide a safe and effective aid in correcting impaired carbohydrate metabolism".
However, he warned that the supplement can not work in isolation.
"The maintenance of healthy blood sugar levels through physical exercise and an appropriate dietary regimen is a pivotal step in preventing impaired glucose tolerance with all the possible later complications," he said.
The seminar on Madeglucyl will be held at Vitafoods on 12 May at 11:40am.
Vitafoods is Europe's largest nutraceutical trade show, which runs from 10-12 May 2005 in Geneva.
Indena, a privately owned Italian company, reported €140 million in consolidated turnover in 2004, mostly generated abroad.
The phyto-chemical research is carried out in Indena's Settala Research Center, near Milan.